Trip.com Shares Tumble After Q1 Profit Drops and Weak Revenue Growth Outlook 
Cerebras Revenue Forecast Tops Expectations, but Margin Concerns Weigh on Stock 
Fortescue Faces Class Action Over Sexual Harassment Claims at Australian Mining Sites 
SpaceX Stock Rebounds After Sharp Selloff, But Valuation Concerns Persist 
WiseTech Global Denies Knowledge of Investigation Into Founder Richard White 
Pelosi Discloses Major Intel and Uber Call Option Purchases Worth Up to $6 Million 
Baseten Secures $1.5 Billion Funding at $13 Billion Valuation Amid AI Infrastructure Boom 
Nike CFO Shake-Up Fuels Concerns Over Turnaround Strategy 
FedEx Stock Drops After Weak 2026 Earnings Forecast Despite Strong Q4 Results 
Ryan Cohen Rejects GameStop Pay Package, Prepares New eBay Acquisition Plan 
SK Hynix Targets $29.4 Billion Nasdaq Listing to Expand AI Chip Business 
Trump Orders DOJ Investigation Into Exxon, Chevron Over High Gas Prices 
Samsung and SK Hynix Shares Jump After Micron Earnings Boost AI Chip Optimism 
Meta Pauses Employee Activity Tracking Program Over Data Security Concerns 
Alibaba Shares Fall After Anthropic Alleges Massive AI Model Distillation Campaign 
Samsung Electronics Stock Surges on Report of Massive $59 Billion Share Buyback Plan 
SANTA MONICA, Calif., Feb. 24, 2016 -- Kite Pharma, Inc., (Nasdaq:KITE) today announced that it will report fourth quarter and full year 2015 financial results on Monday, February 29, 2016 after market close, and will host a conference call to discuss financial results and provide a business update at 4:30 PM Eastern Time (1:30 PM Pacific Time).
Audio Webcast
Interested parties may access a live audio webcast of the conference call on the Investors section of Kite’s website, www.kitepharma.com. A replay of the webcast will be available on the website for approximately 30 days.
Dial-In Information
Live (U.S. / Canada): (877) 301-8565
Live (International): (678) 562-4240
Confirmation number: 45173015
About Kite Pharma
Kite Pharma, Inc., is a clinical-stage biopharmaceutical company engaged in the development of novel cancer immunotherapy products, with a primary focus on engineered autologous cell therapy (eACT™) designed to restore the immune system's ability to recognize and eradicate tumors. Kite is based in Santa Monica, CA. For more information on Kite Pharma, please visit www.kitepharma.com. Sign up to follow @KitePharma on Twitter at www.twitter.com/kitepharma.
CONTACT: Greg Mann VP, Investor Relations [email protected] For Media: Justin Jackson Burns McClellan (212) 213-0006 [email protected]
